Ivosidenib or Enasidenib Combined with Standard Induction Chemotherapy Is Well Tolerated and Active in Patients with Newly Diagnosed AML with an IDH1 or IDH2 Mutation: Initial Results from a Phase 1 Trial
Year: 2017
Type: conference-abstract
Source: Blood
Authors: Eytan M. Stein, Courtney D. DiNardo, Alice S. Mims, Michael R. Savona, Keith Pratz, Anthony S. Stein, Amir T. Fathi, Richard M. Stone, Daniel A. Pollyea, Olatoyosi Odenike, Bob Lowenberg, Hartmut Döhner, Gary J. Schiller, Ira V. Gupta, Salah Nabhan, Vickie Zhang, Caroline Almon, Michael Cooper, Martin S. Tallman
Institutions: Memorial Sloan Kettering Cancer Center, The University of Texas MD Anderson Cancer Center, The Ohio State University, Vanderbilt University, Vanderbilt University Medical Center, Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, City Of Hope National Medical Center, City of Hope, Massachusetts General Hospital, Dana-Farber Cancer Institute, University of Colorado Cancer Center, University of Colorado Denver, University of Chicago Medicine Comprehensive Cancer Center, Erasmus MC, University Hospital Ulm, University of California, Los Angeles, Celgene (United States), Agios Pharmaceuticals (United States)
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2910076617